Baricitinib May Shorten Recovery Time in Hospitalized COVID-19 Patients
Remdesivir -- from Gilead Sciences -- has previously been shown to reduce recovery time to an average of four days. Patients who also received Lilly's anti-inflammatory drug baricitinib (sold as Olumiant to treat rheumatoid arthritis) recovered one day sooner than those who took remdesivir alone, according to the company, the Associated Press reported. Recovery is defined as being well enough to leave the hospital.
The findings from the 1,000-person study, sponsored by the U.S. National Institute of Allergy and Infectious Diseases, were released Monday. The study has not been published or reviewed by independent scientists, but U.S. health officials said Lilly's statement about the results was accurate, the AP reported.
The possible emergency use of baricitinib for hospitalized COVID-19 patients will be discussed with U.S. regulators, Lilly said.
© 2020 HealthDay. All rights reserved.
Posted: September 2020
Further Support and Information on COVID-19
Read this next
FRIDAY, Sept. 18, 2020 -- More than half of hospitalized pregnant women with COVID-19 are asymptomatic at admission, while pregnant women hospitalized for COVID-19-related illness have...
FRIDAY, Sept. 18, 2020 -- The proportion of inpatients with COVID-19 who wear eyeglasses for extended daily periods is lower than in the general population, according to a study published...
FRIDAY, Sept. 18, 2020 -- Older adults are feeling more isolated during the COVID-19 pandemic, according to a report published online Sept. 14 based on the results of the University...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.